Fulgent Genetics Statistics
Want to see FLGT full AI Analyst Report?
Fulgent Genetics (FLGT) Stock Statistics & Valuation Metrics
Total Valuation
Fulgent Genetics has a market cap or net worth of $676.40M. The enterprise value is $320.97M.
- Market Cap
- $676.40M
- Enterprise Value
- $320.97M
Share Statistics
Fulgent Genetics has 27,939,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,939,000
- Owned by Insiders
- 39.41%
- Owned by Institutions
- 42.55%
Financial Efficiency
Fulgent Genetics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -7.09%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -7.09%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 245.38K
- Profits Per Employee
- -46.02K
- Employee Count
- 1,315
- Asset Turnover
- 0.27
- Inventory Turnover
- 18.09
Valuation Ratios
The current PE Ratio of Fulgent Genetics is -7.80. Fulgent Genetics’s PEG ratio is 0.12.
- PE Ratio
- -7.80
- PS Ratio
- 2.04
- PB Ratio
- 0.67
- Price to FCF
- -480.75
- Price to Operating Cash Flow
- 46.19
- PEG Ratio
- 0.12
Income Statement
In the last 12 months, Fulgent Genetics had revenue of 322.67M and earned -60.51M in profits. Earnings per share was -1.97.
- Revenue
- 322.67M
- Gross Profit
- 130.88M
- Operating Income
- -91.10M
- Pretax Income
- -70.03M
- Net Income
- -60.51M
- EBITDA
- -45.83M
- Earnings Per Share (EPS)
- -1.97
Cash Flow
In the last 12 months, operating cash flow was 14.43M and capital expenditures -15.83M, giving a free cash flow of -1.40M billion.
- Operating Cash Flow
- 14.43M
- Free Cash Flow
- -1.40M
- Free Cash Flow per Share
- -0.05
Dividends & Yields
Fulgent Genetics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.21%
- Earnings Yield
- -13.57%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- -15.97%
- 50-Day Moving Average
- 21.38
- 200-Day Moving Average
- 19.02
- Relative Strength Index (RSI)
- 59.52
- Average Volume (3m)
- 327.04K
Important Dates
Fulgent Genetics upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Fulgent Genetics as a current ratio of 6.48, with Debt / Equity ratio of 0.69%
- Current Ratio
- 6.48
- Quick Ratio
- 6.35
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.93
- Interest Coverage Ratio
- -1214.61
Taxes
In the past 12 months, Fulgent Genetics has paid -8.39M in taxes.
- Income Tax
- -8.39M
- Effective Tax Rate
- 0.12
Enterprise Valuation
Fulgent Genetics EV to EBITDA ratio is -8.20, with an EV/FCF ratio of -422.75.
- EV to Sales
- 1.79
- EV to EBITDA
- -8.20
- EV to Free Cash Flow
- -422.75
- EV to Operating Cash Flow
- 41.02
Balance Sheet
Fulgent Genetics has $292.74M in cash and marketable securities with $1.96M in debt, giving a net cash position of $290.78M billion.
- Cash & Marketable Securities
- $292.74M
- Total Debt
- $1.96M
- Net Cash
- $290.78M
- Net Cash Per Share
- $10.41
- Tangible Book Value Per Share
- $28.34
Margins
Gross margin is 33.82%, with operating margin of -38.55%, and net profit margin of -27.53%.
- Gross Margin
- 33.82%
- Operating Margin
- -38.55%
- Pretax Margin
- -29.97%
- Net Profit Margin
- -27.53%
- EBITDA Margin
- -21.85%
- EBIT Margin
- -29.90%
Analyst Forecast
The average price target for Fulgent Genetics is $25.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $25.00
- Price Target Upside
- 3.26% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- 4.67%
- EPS Growth Forecast
- -120.44%
Scores
- Smart Score
- 5
- AI Score
- 60

